Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Javelin Gets FDA Guidance On Intranasal Ketamine For Pain

This article was originally published in The Pink Sheet Daily

Executive Summary

Company plans to file via the 505(b)(2) pathway for military and emergency civilian use in 2008.

You may also be interested in...



Javelin’s Dyloject On Track For 1H 2009 NDA Filing; PMI-150 Needs Additional Efficacy Study

Following Dec. U.K. Dyloject launch, firm plans to market the NSAID in other European markets during the second half of next year.

Javelin’s Dyloject On Track For 1H 2009 NDA Filing; PMI-150 Needs Additional Efficacy Study

Following Dec. U.K. Dyloject launch, firm plans to market the NSAID in other European markets during the second half of next year.

Javelin’s Intranasal Morphine Meets Phase III Primary Endpoint

Morphine delivered using Javelin’s proprietary technology could offer simpler, effective alternative to other postoperative opioids, firm says.

Topics

UsernamePublicRestriction

Register

LL1134420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel